# Changelog


## üîç 04.01.2026 –û–±–Ω–∞—Ä—É–∂–µ–Ω–Ω—ã–µ –æ—à–∏–±–∫–∏

### –ö—Ä–∏—Ç–∏—á–µ—Å–∫–∏–µ –ø—Ä–æ–±–ª–µ–º—ã:

#### 1. **–ù–µ–ø–æ–ª–Ω–∞—è —Å–º–µ–Ω–∞ –ø–∞—Ä–∞–º–µ—Ç—Ä–æ–≤ –ø—Ä–∏ –≤—ã–±–æ—Ä–µ —Å—Ü–µ–Ω–∞—Ä–∏—è**
- ‚úÖ **–ò—Å–ø—Ä–∞–≤–ª–µ–Ω–æ**: –ù–µ–π—Ä–æ–º–æ–¥—É–ª—è—Ç–æ—Ä—ã –º–µ–Ω—è—é—Ç—Å—è
- ‚ùå **–ü—Ä–æ–±–ª–µ–º–∞**: –ö–∞—É–∑–∞–ª—å–Ω—ã–µ –≤–µ—Å–∞, ignition –ø–∞—Ä–∞–º–µ—Ç—Ä—ã, spatial coupling –ù–ï –ú–ï–ù–Ø–Æ–¢–°–Ø
- **–ü–æ—Å–ª–µ–¥—Å—Ç–≤–∏–µ**: –í–∏–¥–∂–µ—Ç—ã –ø–æ–∫–∞–∑—ã–≤–∞—é—Ç –Ω–µ–∫–æ—Ä—Ä–µ–∫—Ç–Ω—É—é –¥–∏–Ω–∞–º–∏–∫—É –¥–ª—è N2/N3/propofol

#### 2. **–û—Ç—Å—É—Ç—Å—Ç–≤–∏–µ —Ñ–∞—Ä–º–∞–∫–æ–∫–∏–Ω–µ—Ç–∏–∫–∏**
- ‚ùå Psilocybin –∫–æ–Ω—Ü–µ–Ω—Ç—Ä–∞—Ü–∏—è –∫–æ–Ω—Å—Ç–∞–Ω—Ç–Ω–∞ (–∏–∑ —Å–ª–∞–π–¥–µ—Ä–∞)
- ‚úÖ **–î–æ–ª–∂–Ω–∞**: T_max = 90 min, exponential decay (T_¬Ω = 180 min)

#### 3. **–£–ø—Ä–æ—â—ë–Ω–Ω–∞—è —Å–µ–Ω—Å–æ—Ä–Ω–∞—è —Å—Ç–∏–º—É–ª—è—Ü–∏—è**
- ‚ùå –ö–æ–Ω—Å—Ç–∞–Ω—Ç–∞ `0.4 * A[i]` –¥–ª—è –≤—Å–µ—Ö —Ä–µ–≥–∏–æ–Ω–æ–≤
- ‚úÖ **–î–æ–ª–∂–Ω–∞**: Visual regions (V1-IT) –≤—ã—Å–æ–∫–∞—è, frontal –Ω–∏–∑–∫–∞—è

#### 4. **–ù–µ—Ç–æ—á–Ω–∞—è –∏–Ω–∏—Ü–∏–∞–ª–∏–∑–∞—Ü–∏—è —Å–æ—Å—Ç–æ—è–Ω–∏–π**
- ‚ùå Random noise ¬±0.5 —Å–ª–∏—à–∫–æ–º –≤–µ–ª–∏–∫ –¥–ª—è –Ω–µ–∫–æ—Ç–æ—Ä—ã—Ö —Å—Ü–µ–Ω–∞—Ä–∏–µ–≤
- ‚úÖ **–î–æ–ª–∂–Ω–∞**: Region-specific –∏–Ω–∏—Ü–∏–∞–ª–∏–∑–∞—Ü–∏—è (DMN –≤—ã—à–µ –¥–ª—è wake, –Ω–∏–∂–µ –¥–ª—è sleep)

#### 5. **–û—Ç—Å—É—Ç—Å—Ç–≤–∏–µ —Ä–µ–≥–∏–æ–Ω–∞–ª—å–Ω—ã—Ö –ø–∞—Ä–∞–º–µ—Ç—Ä–æ–≤**
- ‚ùå –í—Å–µ —Ä–µ–≥–∏–æ–Ω—ã –∏–º–µ—é—Ç –æ–¥–∏–Ω–∞–∫–æ–≤—ã–µ Œ≤_ACh, Œ≤_NE gains
- ‚úÖ **–î–æ–ª–∂–Ω—ã**: Receptor density maps (Palomero-Gallagher & Zilles, 2018)

---

### üìê –°–æ–æ—Ç–≤–µ—Ç—Å—Ç–≤–∏–µ –º–∞—Ç–µ–º–∞—Ç–∏—á–µ—Å–∫–æ–π —Ñ–æ—Ä–º–∞–ª–∏–∑–∞—Ü–∏–∏

#### –ü—Ä–æ–≤–µ—Ä–∫–∞ —É—Ä–∞–≤–Ω–µ–Ω–∏–π:

##### ‚úÖ –ö–æ—Ä—Ä–µ–∫—Ç–Ω–æ —Ä–µ–∞–ª–∏–∑–æ–≤–∞–Ω–æ:
1. dL/dt homeostasis: `0.5 * L[i] * (1 - L[i]/10)`
2. Neuromodulatory drive: `0.5 * (L_target - L[i])`
3. Causal inputs: `w_CL * C[i] + w_SL * S[i]`
4. Ignition threshold: `sigmoid(k_ign * (L[i] - L_thresh_eff))`
5. Binding efficiency: `k_bind * L[i] * C[i] * (10 - C[i]) * g_att`
6. DMN-specific suppression: `alpha_psych * Psilo * S[i]` (—Ç–æ–ª—å–∫–æ DMN)

##### ‚ùå –û—Ç—Å—É—Ç—Å—Ç–≤—É–µ—Ç –∏–ª–∏ —É–ø—Ä–æ—â–µ–Ω–æ:
1. **Regional receptor gains** (g_m^(i) –≤ —Ñ–æ—Ä–º–∞–ª–∏–∑–∞—Ü–∏–∏)
2. **Time-varying pharmacokinetics** (psilocybin PK model)
3. **Sensory input structure** (I_sens –¥–æ–ª–∂–µ–Ω –±—ã—Ç—å region-specific)
4. **Attention top-down modulation** (–æ—Ç FPN –∫ sensory)
5. **Circadian modulation** (–¥–ª—è ACh/Orx –≤ –¥–ª–∏–Ω–Ω—ã—Ö —Å–∏–º—É–ª—è—Ü–∏—è—Ö)

---

### üé® –ù–æ–≤—ã–π —É–ª—É—á—à–µ–Ω–Ω—ã–π –∫–æ–¥

#### –ö–ª—é—á–µ–≤—ã–µ —É–ª—É—á—à–µ–Ω–∏—è:

1. ‚úÖ **–ü–æ–ª–Ω—ã–µ –ø—Ä–µ—Å–µ—Ç—ã —Å—Ü–µ–Ω–∞—Ä–∏–µ–≤** (–≤—Å–µ –ø–∞—Ä–∞–º–µ—Ç—Ä—ã, –Ω–µ —Ç–æ–ª—å–∫–æ –Ω–µ–π—Ä–æ–º–æ–¥—É–ª—è—Ç–æ—Ä—ã)
2. ‚úÖ **–§–∞—Ä–º–∞–∫–æ–∫–∏–Ω–µ—Ç–∏–∫–∞ psilocybin** (time-dependent –∫–æ–Ω—Ü–µ–Ω—Ç—Ä–∞—Ü–∏—è)
3. ‚úÖ **–†–µ–≥–∏–æ–Ω–∞–ª—å–Ω—ã–µ receptor gains** (13√ó4 –º–∞—Ç—Ä–∏—Ü–∞)
4. ‚úÖ **–°—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω–∞—è —Å–µ–Ω—Å–æ—Ä–Ω–∞—è —Å—Ç–∏–º—É–ª—è—Ü–∏—è** (visual vs frontal)
5. ‚úÖ **Attention modulation** (FPN ‚Üí sensory top-down)
6. ‚úÖ **Improved initialization** (region-specific –¥–ª—è DMN/sensory)
7. ‚úÖ **–î–æ–ø–æ–ª–Ω–∏—Ç–µ–ª—å–Ω—ã–µ –≤–∏–∑—É–∞–ª–∏–∑–∞—Ü–∏–∏** (–∏–∑ Python –ø—Ä–∏–º–µ—Ä–æ–≤):
   - Regional spatial pattern (bar chart)
   - Neuromodulator dynamics
   - Attention timeseries
8. ‚úÖ **Validation metrics** (PCI, clinical state, R¬≤)

#### –¢–æ—á–Ω–æ—Å—Ç—å:

- –í—Å–µ –ø–∞—Ä–∞–º–µ—Ç—Ä—ã –æ—Ç–∫–∞–ª–∏–±—Ä–æ–≤–∞–Ω—ã –ø–æ —Ä–µ—Ñ–µ—Ä–µ–Ω—Å–∞–º (Casali 2013, Carhart-Harris 2012, Fleming 2012)
- Receptor density values –∏–∑ Palomero-Gallagher & Zilles (2018)
- Psilocybin PK –∏–∑ Hasler et al. (2004) + Nour et al. (2016)

---


